{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069153","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.168646+00:00","generated_at":"2026-05-21T23:46:01.993624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bolt Biotherapeutics Q1 2025: operating loss $12.1M; cash $58M; BDC-4182 Phase 1 open","bullets":["Collaboration revenue $1.2M (down from $5.3M in Q1 2024) due to completion of Innovent agreement.","R&D expense $9.5M (down from $16.5M); G&A $3.8M (down from $5.8M) reflecting May 2024 restructuring.","Cash balance $58.0M expected to fund operations and milestones through mid-2026.","BDC-4182 Phase 1 dose-escalation study for gastric/gastroesophageal cancer opened for enrollment in April 2025.","Partnering process initiated for BDC-3042 after AACR 2025 data showed favorable safety and biological activity."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069153","json":"https://secwatch.observer/filing/0000950170-25-069153.json","markdown":"https://secwatch.observer/filing/0000950170-25-069153.md","text":"https://secwatch.observer/filing/0000950170-25-069153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000095017025069153/0000950170-25-069153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000095017025069153/bolt-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:46:01.993624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}